Recent Insider Transactions Derivative • Aug 16
CEO, President & Director exercised options and sold US$122k worth of stock On the 14th of August, Daniel Schmitt exercised options to acquire 121k shares at no cost and sold these for an average price of US$1.01 per share. This trade did not impact their existing holding. For the year to December 2022, Daniel's total compensation was 26% salary and 74% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Daniel currently holds 876.58k shares (0.03663735778353891 of the company). Company insiders have collectively sold US$649k more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jul 19
Actuate Therapeutics, Inc. Announces Receipt of Nasdaq Notice Regarding Market Value of Listed Securities On July 15, 2026, Actuate Therapeutics, Inc. (the Company) received a letter (the Notice) from the listing qualifications department staff (the Staff) of The Nasdaq Stock Market (Nasdaq) notifying the Company that from June 1, 2026 to July 14, 2026, the Company's Market Value of Listed Securities (MVLS) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Notice has no immediate effect on the listing of the Company's common stock, and the Company's common stock continues to trade on the Nasdaq Global Market under the symbol ACTU. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from the date of the Notice, or through January 11, 2027 (the Compliance Date), to regain compliance with respect to the MVLS Requirement. The Notice states that if the Company's MVLS closed at $50 million or more for a minimum of ten consecutive business days during the compliance period ending on the Compliance Date, the Staff will provide written confirmation of compliance. If the Company does not regain compliance by the Compliance Date, Nasdaq will provide written notice to the Company that its securities are subject to delisting. At that time, the Company may appeal any such delisting determination. However, there can be no assurance that, if the Company receives a delisting notice from the Staff and appeals the delisting determination, such appeal would be successful. Alternatively, the Company would consider applying for transfer to The Nasdaq Capital Market (the Capital Market). The Company intends to actively monitor the Company's MVLS between now and the Compliance Date and will take all reasonable measures available to the Company to regain compliance with the MVLS Requirement. While the Company is exercising diligent efforts to maintain the listing of its common stock on Nasdaq, there can be no assurance that the Company will be able to regain or maintain compliance with the applicable continued listing standards set forth in the Nasdaq Listing Rules. Announcement • Jun 29
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Index Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Index 
